SAINT PAUL, Minn., March 19, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology leader, today announced that it has entered into a worldwide distribution agreement with Restech Respiratory Technology (Restech Srl), a privately held company spun-off from the Politecnico di Milano, Italy, to market and distribute the Resmon Pro, Forced Oscillation Technique (FOT) device. Manufactured by Restech Srl, the Resmon Pro aids in the diagnosis and treatment of respiratory disease. Typically, the diagnosis of common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) involve complex measurements and maximum patient effort. Restech developed patented technology to determine the breath-by-breath presence and severity of expiratory flow limitation (EFL) during quiet breathing. Using the Resmon Pro, a physician can detect the presence, severity and reversibility of EFL, and evaluate the degree of airflow obstruction and shortness-of-breath experienced by the patient.
Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "Our agreement with Restech is an example of how MGC Diagnostics will execute strategic partnerships with emerging technology providers, both within the university sciences and entrepreneurial start-up sectors. Leveraging MGC Diagnostics global sales, marketing, and support network provides emerging technology companies best-in-class access to cardiorespiratory healthcare professionals and their patients throughout the world."
About Restech Respiratory TechnologyRestech SRL is a spinoff company of Politecnico di Milano derived from a Bioengineering Department research team of the Biomedical Technology Laboratory (TBMLab). Their primary focus is in the development of innovative products and services for the diagnosis, monitoring and management of patients affected by respiratory diseases.
About MGC DiagnosticsMGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.
Cautionary Statement Regarding Forward Looking StatementsFrom time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:
Gregg O. Lehman, Ph.D.Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation
Lytham Partners, LLCChief Executive Officer
(602) 889-9700(651) firstname.lastname@example.org
|SOURCE MGC Diagnostics Corporation|
Copyright©2012 PR Newswire.
All rights reserved